CDSCO Panel Seeks Safety Data on 5% Lenalidomide TDS Before Clearing 8% Patch Trial
New Delhi: The Subject Expert Committee (SEC) under the Oncology division of the Central Drugs Standard Control Organisation (CDSCO) has not granted approval to the proposal submitted by Raptim Research Pvt. Ltd. for conducting a bioavailability/bioequivalence (BA/BE) study of Lenalidomide TDS 8% - LLD-TDS-009 patch, citing the requirement for submission of safety data on the lower-strength formulation before proceeding.
The matter was discussed during the SEC Oncology meeting held on 8th July 2025.
Raptim Research presented the BA/BE study protocol PR/BE/24/370, Version 00, dated 15th January 2025, for the Lenalidomide TDS 8% patch (50 cm² with 81 cm² overlay). The protocol was submitted for approval concerning studies intended for export purposes only.
Following detailed discussions, the committee advised that the firm should submit safety data of low-strength Lenalidomide TDS 5% using Derma Roller technology before initiating any studies involving the higher-strength Lenalidomide TDS 8% formulation in healthy human subjects.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.